Consistent mutation status within histologically heterogeneous lung cancer lesions

Area of Science:

• Oncology
• Molecular Pathology
• Cancer Genomics

Background:

• Activating epidermal growth factor receptor (EGFR) and KRAS mutations define key molecular subgroups in non-small-cell lung cancer (NSCLC).
• These mutations predict response to EGFR inhibitor therapies.
• The clonal stability and temporal occurrence of these mutations within primary tumors remain debated.

Purpose of the Study:

• To investigate the presence and distribution of EGFR and KRAS mutations within histologically diverse regions of primary NSCLC.
• To assess the consistency of these oncogenic mutations across different tumor areas.

Main Methods:

• Analysis of formalin-fixed paraffin-embedded tumor specimens from NSCLC patients with known EGFR or KRAS mutations.
• Manual microdissection of three distinct morphological areas from each tumor.
• Mutation analysis of dissected tumor regions.

Main Results:

• Consistent EGFR and KRAS mutation status was observed in all analyzed histological areas within each primary tumor.
• No significant variation in mutation status was detected across different regions of the same tumor.

Conclusions:

• Activating EGFR and KRAS mutations are stable oncogenic events present uniformly throughout primary NSCLC.
• Histological heterogeneity does not impact the presence of these key mutations.
• Any section of the primary tumor is likely representative for EGFR and KRAS mutation testing in molecular diagnostics.